Advertisement

Molecular Biology Reports

, Volume 46, Issue 2, pp 2387–2394 | Cite as

Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan

  • Faria FatimaEmail author
  • Saima Saleem
  • Abdul Hameed
  • Ghulam Haider
  • Syed Aqib Ali Zaidi
  • Madiha Kanwal
  • Sitwat Zehra
  • Abid Azhar
Original Article
  • 71 Downloads

Abstract

Chemokine CC receptor type 5 (CCR5) is a cell surface receptor that has high affinity for chemotropic cytokines called chemokines. The CCR5 gene contains a 32 base pairs (bp) deletion (CCR5Δ32). This deletion may result in a malformed and nonfunctional receptor, reported to be responsible for the development and dissemination of different cancers. CCR5Δ32 exists in two allelic forms i.e. deletion (D) and wild type (WT). This study aims to detect the role of CCR5Δ32 in breast cancer development. Blood samples were collected from breast cancer patients (330) and controls of same gender (306). Along with this histopathologically diagnosed malignant tissue samples were also excised from breast lesions of 100 patients. Genetic variations within the blood and tissue samples were examined by PCR then observed through gel electrophoresis and confirmed by direct DNA sequencing. Obtained DNA sequences were aligned and analyzed by MEGA6 software. Genotypic and association analyses were done by SPSS software version 17.0. Deletion of 32 bp in CCR5 gene has been analyzed. Genotypic variations of CCR5Δ32 are; homozygous wild type (WT/WT), heterozygous deletion (WT/D) and homozygous deletion (D/D). Statistical analyses of CCR5Δ32 data revealed that WT/D was significantly higher in blood samples of breast cancer patients (7.27% (24/330)) as compare to controls (1.30% (4/306)). In tumor tissue samples WT/WT being the most frequent genotype (99.00% (99/100)) with 1.00 (1/100) of D/D which suggested that it may be acquired. Hence, association analysis showed that CCR5Δ32 is positively associated with breast cancer in Pakistan (p < 0.001). The risk ratio of CCR5Δ32 was 5.6610 (95% confidence interval: 2.0377 to 15.7267) and odds ratio was calculated to be 6.0335 (95% confidence interval: 2.1288 to 17.0999) which signifies that deletion also increases the risk of breast cancer development. Moreover, association analyses also revealed that clinicopathological features do not have any impact on the CCR5Δ32 genotype of breast cancer. This suggests that deletion of 32 bp in CCR5 gene may be associated with breast cancer. CCR5 signals the activation and migration of immune cells at the site of tumor formation. Because of deletion; deformed CCR5 receptor might be unable to express and function properly which may subdue the immunity against cancer hence, leading to its progression.

Keywords

Breast cancer Chemokines receptor CCR5 gene 32 bp deletion Metastasis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH (2002) Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13:754–758Google Scholar
  2. 2.
    Abdolmohammadi R, Shahbazi Azar S, Khosravi A, Shahbazi M (2016) CCR5 polymorphism as a protective factor for hepatocellular carcinoma in hepatitis B virus-infected iranian patients asian pacific. J Cancer Prev 17:4643–4646Google Scholar
  3. 3.
    Al-Jaberi SA, Ben-Salem S, Messedi M, Ayadi F, Al-Gazali L, Ali BR (2013) Determination of the CCR532 frequency in Emiratis and Tunisians and the screening of the CCR5 gene for novel alleles in. Emir Gene 529:113–118.  https://doi.org/10.1016/j.gene.2013.07.062 CrossRefGoogle Scholar
  4. 4.
    Aldinucci D, Colombatti A (2014) The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm 2014:12.  https://doi.org/10.1155/2014/292376 CrossRefGoogle Scholar
  5. 5.
    Aoki MN, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA (2009) CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 23:429–435Google Scholar
  6. 6.
    Barashi N et al (2013) Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology 58:1021–1030.  https://doi.org/10.1002/hep.26403 CrossRefGoogle Scholar
  7. 7.
    Chavhan AB, Pawar SS, Jadhao RG, Patil KG (2013) Distribution of CC-chemokine receptor-5-∆32 allele among the tribal and caste population of Vidarbha region of Maharashtra state. Indian J Hum Genet 19:65–70.  https://doi.org/10.4103/0971-6866.112894 CrossRefGoogle Scholar
  8. 8.
    Degerli N, Yilmaz E, Bardakci F (2005) The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 38:248–252.  https://doi.org/10.1016/j.clinbiochem.2004.11.001 CrossRefGoogle Scholar
  9. 9.
    Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA (2006) Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol, Prev Biomark 15:726–731.  https://doi.org/10.1158/1055-9965.epi-05-0797 CrossRefGoogle Scholar
  10. 10.
    Eskandari-Nasab E, Hashemi M, Ebrahimi M, Amininia S, Bahari G, Mashhadi MA, Taheri M (2014) Evaluation of CCL5 -403 G> A and CCR5 Delta32 gene polymorphisms in patients with breast cancer Cancer Biomark 14:343–351  https://doi.org/10.3233/cbm-140411 CrossRefGoogle Scholar
  11. 11.
    Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386.  https://doi.org/10.1002/ijc.29210 CrossRefGoogle Scholar
  12. 12.
    Gawron AJ et al (2011) Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk polish population Scandinavian. J Gastroenterol 46:333–340.  https://doi.org/10.3109/00365521.2010.537679 Google Scholar
  13. 13.
    Gonzalez-Martin A, Mira E, Manes S (2012) CCR5 in cancer immunotherapy: More than an “attractive” receptor for. T cells. Oncoimmunology 1:106–108.  https://doi.org/10.4161/onci.1.1.17995 CrossRefGoogle Scholar
  14. 14.
    Guleria K, Sharma S, Manjari M, Uppal MS, Singh NR, Sambyal V (2012) R72P, PIN3 Ins16bp polymorphisms of TP53 and CCR5∆32 in north Indian breast cancer patients. Asian Pacific J Cancer Prev 13:3305–3311CrossRefGoogle Scholar
  15. 15.
    Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A (2008) SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer Pathol Oncol Res 14:45–50.  https://doi.org/10.1007/s12253-008-9007-2 CrossRefGoogle Scholar
  16. 16.
    Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S (2012) Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol 31:1418–1424.  https://doi.org/10.1089/dna.2012.1716 CrossRefGoogle Scholar
  17. 17.
    Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144.  https://doi.org/10.1016/j.molmed.2010.01.003 CrossRefGoogle Scholar
  18. 18.
    Libert F et al (1998) The ∆ccr5 mutation conferring protection against HIV-1 in caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 7:399–406.  https://doi.org/10.1093/hmg/7.3.399 CrossRefGoogle Scholar
  19. 19.
    Lu Y et al (1999) Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. Int J Infect Dis 3:186–191CrossRefGoogle Scholar
  20. 20.
    Manes S et al (2003) CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 198:1381–1389.  https://doi.org/10.1084/jem.20030580 CrossRefGoogle Scholar
  21. 21.
    Maniatis T, Fritsch EF, Sambrook J (1982) Molecular cloning: a laboratory manual vol 545. Cold spring harbor laboratory, New YorkGoogle Scholar
  22. 22.
    McHugh ML (2009) The odds ratio: calculation, usage, and interpretation. Biochem Med 19:120–126CrossRefGoogle Scholar
  23. 23.
    Navratilova Z (2006) Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150:191–204CrossRefGoogle Scholar
  24. 24.
    Nkenfou CN, Mekue LCM, Nana CT, Kuiate JR (2013) Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3′A genetic polymorphisms in HIV-1 infected and uninfected patients in the West Region of Cameroon. BMC Res Notes 6:288CrossRefGoogle Scholar
  25. 25.
    Nomiyama H, Osada N, Yoshie O (2011) A family tree of vertebrate chemokine receptors for a unified nomenclature. Dev Comp Immunol 35:705–715CrossRefGoogle Scholar
  26. 26.
    Oliveira, CECd et al (2014) CC chemokine receptor 5: the interface of host. Immun Cancer Dis Mark 2014:8.  https://doi.org/10.1155/2014/126954 Google Scholar
  27. 27.
    Rahimi H, Farajollahi MM, Hosseini A (2014) Distribution of the mutated delta 32 allele of CCR5 co-receptor gene in Iranian population medical. J Islamic Repub Iran 28:140Google Scholar
  28. 28.
    Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256:137–165CrossRefGoogle Scholar
  29. 29.
    Rita BC et al (2009) CCR5 Proinflammatory allele in prostate cancer risk annals of the New York. Acad Sci 1155:289–292 doi.  https://doi.org/10.1111/j.1749-6632.2008.03691.x CrossRefGoogle Scholar
  30. 30.
    Salem A-H, Batzer MA (2007) Distribution of the HIV resistance CCR5-∆32 allele among Egyptians and Syrians Mutation Research/Fundamental and Molecular. Mech Mutagenesis 616:175–180Google Scholar
  31. 31.
    Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual. vol Ed. 2. Cold spring harbor laboratory press, New YorkGoogle Scholar
  32. 32.
    Sambyal V, Manjari M, Sudan M, Uppal MS, Singh NR, Singh H, Guleria K (2015) No association between the CCR5∆32 polymorphism and sporadic esophageal cancer in Punjab, North-West India Asian Pacific. J Cancer Prev 16:4291–4295Google Scholar
  33. 33.
    Srivastava A, Pandey S, Choudhuri G, Mittal B (2008) CCR5 ∆32 polymorphism: associated with gallbladder cancer susceptibility scandinavian. J Immunol 67:516–522Google Scholar
  34. 34.
    Stone MJ, Hayward JA, Huang C, E Huma Z, Sanchez J (2017) Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci 18:342CrossRefGoogle Scholar
  35. 35.
    Szumilas M (2010) Explaining odds ratios. J Can Acad Child Adolesc Psychiatry 19:227CrossRefGoogle Scholar
  36. 36.
    Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30:2725–2729CrossRefGoogle Scholar
  37. 37.
    Tanyel C, Cincin Z, Gokcen-Rohlig B, Bektas-Kayhan K, Unur M, Cakmakoglu B (2013) Effects of genetic variants of CCR5 chemokine receptors on oral squamous cell carcinoma. Genet Mol Res 12:5714–5720CrossRefGoogle Scholar
  38. 38.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012 CA: a cancer. J Clin 65:87–108.  https://doi.org/10.3322/caac.21262 Google Scholar
  39. 39.
    Umansky V, Blattner C, Gebhardt C, Utikal J (2017) CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma cancer immunology. Immunotherapy 66:1015–1023CrossRefGoogle Scholar
  40. 40.
    V Downer M et al (2002) Regional variation in CCR5-Delta 32 gene distribution among women from the USHIV Epidemiology Research Study (HERS). Genes Immun.  https://doi.org/10.1038/sj.gene.6363884 Google Scholar
  41. 41.
    Velasco-Velázquez M, Pestell RG (2013) The CCL5/CCR5 axis promotes metastasis in basal. Breast Cancer. Oncoimmunology 2:e23660CrossRefGoogle Scholar
  42. 42.
    Von Luettichau I et al (2008) A complex pattern of chemokine receptor expression is seen in osteosarcoma. BMC Cancer 8:23CrossRefGoogle Scholar
  43. 43.
    Wang F-S et al (2003) Population survey of CCR5 ∆32, CCR5 m303, CCR2b 64I, and SDF1 3 A allele frequencies in indigenous Chinese Healthy Individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups JAIDS. J Acquir Immune Defic Syndr 32:124–130CrossRefGoogle Scholar
  44. 44.
    Weng C-J et al (2010) Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral. Cancer Oral Oncol 46:767–772CrossRefGoogle Scholar
  45. 45.
    Zafiropoulos A, Crikas N, Passam A, Spandidos D (2004) Significant involvement of CCR2–64I and CXCL12–3a in the development of sporadic breast cancer. J Med Genet 41:e59–e59CrossRefGoogle Scholar
  46. 46.
    Zheng B et al (2006) Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res 26:3669–3674Google Scholar
  47. 47.
    Zlotnik A, Yoshie O (2012) The chemokine superfamily revisited Immunity 36:705–716Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Faria Fatima
    • 1
    Email author
  • Saima Saleem
    • 1
  • Abdul Hameed
    • 2
  • Ghulam Haider
    • 3
  • Syed Aqib Ali Zaidi
    • 1
  • Madiha Kanwal
    • 1
  • Sitwat Zehra
    • 1
  • Abid Azhar
    • 1
  1. 1.The Karachi Institute of Biotechnology and Genetic Engineering (KIBGE)University of KarachiKarachiPakistan
  2. 2.Institute of Biomedical and Genetic Engineering (IB&GE)IslamabadPakistan
  3. 3.Department of OncologyJinnah Postgraduate Medical Centre (JPMC)KarachiPakistan

Personalised recommendations